365betÌåÓýÔÚÏßÊÀ½ç±­

(Reuters) -The U.S. Food and Drug Administration will meet its targets for completing reviews of new drugs despite mass firings at the agency under the Trump administration, its chief said.

In an interview posted on a prominent industry blog, FDA commissioner Martin Makary also said there were no plans for major reorganization at the agency, unlike those planned by Health and Human Services Secretary Robert F. Kennedy Jr. at its other health counterparts.